$1,010.31
0.41% day before yesterday
NYSE, Dec 05, 10:09 pm CET
ISIN
US5324571083
Symbol
LLY

Eli Lilly and Company Stock price

$1,010.31
+84.50 9.13% 1M
+244.63 31.95% 6M
+238.31 30.87% YTD
+184.69 22.37% 1Y
+641.02 173.58% 3Y
+862.89 585.33% 5Y
+923.93 1,069.61% 10Y
+958.84 1,862.91% 20Y
NYSE, Closing price Fri, Dec 05 2025
-4.18 0.41%

New AI Insights on Eli Lilly and Company Insights AI Insights on Eli Lilly and Company

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$955.1b
Enterprise Value
$987.7b
Net debt
$32.6b
Cash
$9.9b
Shares outstanding
945.8m
Valuation (TTM | estimate)
P/E
49.3 | 42.0
P/S
16.1 | 15.1
EV/Sales
16.6 | 15.6
EV/FCF
153.5
P/B
40.1
Dividends
DPS
$6.00
Yield 1Y | 5Y
0.6% | 0.9%
Growth 1Y | 5Y
15.4% | 15.2%
Payout 1Y | 3Y
44.4% | 55.9%
Increased
11 Years
Financials (TTM | estimate)
Revenue
$59.4b | $63.2b
EBITDA
$28.3b | $27.6b
EBIT
$26.4b | $25.8b
Net Income
$18.4b | $22.7b
Free Cash Flow
$6.4b
Growth (TTM | estimate)
Revenue
45.4% | 40.2%
EBITDA
75.6% | 46.7%
EBIT
82.8% | 51.3%
Net Income
120.0% | 114.7%
Free Cash Flow
382.9%
Margin (TTM | estimate)
Gross
83.0%
EBITDA
47.6% | 43.7%
EBIT
44.4%
Net
31.0% | 36.0%
Free Cash Flow
10.8%
Financial Health
Equity Ratio
18.0%
Return on Equity
74.6%
ROCE
35.3%
ROIC
25.1%
Debt/Equity
1.8
More
EPS
$20.5
FCF per Share
$6.8
Short interest
0.9%
Employees
47k
Rev per Employee
$960.0k
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

37 Analysts have issued a Eli Lilly and Company forecast:

28x Buy
76%
9x Hold
24%

Analyst Opinions

37 Analysts have issued a Eli Lilly and Company forecast:

Buy
76%
Hold
24%

Financial data from Eli Lilly and Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
59,420 59,420
45% 45%
100%
- Direct Costs 10,084 10,084
29% 29%
17%
49,336 49,336
49% 49%
83%
- Selling and Administrative Expenses 10,387 10,387
28% 28%
17%
- Research and Development Expense 12,558 12,558
19% 19%
21%
28,287 28,287
76% 76%
48%
- Depreciation and Amortization 1,896 1,896
14% 14%
3%
EBIT (Operating Income) EBIT 26,391 26,391
83% 83%
44%
Net Profit 18,412 18,412
120% 120%
31%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Neutral
PRNewsWire
about one hour ago
In addition to meeting the primary endpoint of non-inferiority for  overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to  78.5% for ibrutinib in the intent-to-treat (ITT) population Progression-free survival data were immature but trended in favor of pirtobrutinib with a 43% reduction of the risk of disease progression or d...
Neutral
The Motley Fool
one day ago
Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and some upcoming catalysts.
Positive
The Motley Fool
2 days ago
Lilly's market cap recently touched $1 trillion. Forecasts for the GLP-1 market are evolving.
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 47,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today